Mirum Pharmaceuticals, Inc. (MIRM) News
Track canonical SquawkNews coverage tagged to MIRM, Mirum Pharmaceuticals, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 16 indexed stories across 12 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
US FDA approves Mirum's drug for rare bone disorder
The US Food and Drug Administration has approved Mirum Pharmaceuticals' NASDAQ:MIRM drug to treat a rare bone disorder, the regulator said on Friday.
REGULATION | Sep 25, 2026, 06:57 PM UTC
L
INCY, MIRM Slip Into FDA’s Weekend Decision Date On Shared Rare-Disease Pill
Shares of Incyte (INCY) and Mirum Pharmaceuticals (MIRM) both eased on Friday after opening higher as traders waited for a weekend ruling from U.S. regulators on their shared rare-disease pill zilurgisertib.INCY opened u
REGULATION | Sep 25, 2026, 06:44 PM UTC
H
MIRM: Commercial growth, pipeline catalysts, and global expansion position the business for continued momentum
Strong Q2 revenue and raised guidance reflect robust commercial growth, especially for LIVMARLI in rare liver diseases. Multiple near-term clinical milestones, commercial team expansion, and international growth are expe
EARNINGS | Sep 15, 2026, 02:07 PM UTC
H
MIRM: Strong Q2 revenue, pipeline catalysts, and global expansion set the stage for continued growth
Q2 revenue reached $176.2 million, prompting raised full-year guidance. LIVMARLI's growth is driven by PFIC expansion and international rollout, while multiple pivotal data readouts and a PDUFA date for zilurgisertib are
EARNINGS | Sep 15, 2026, 01:41 PM UTC
L
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on September 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non
EQUITY | Sep 14, 2026, 08:01 PM UTC
L
MIRM: Pivotal data and regulatory milestones across rare diseases set the stage for significant growth
Upcoming quarters will see pivotal data readouts for HDV, cholestatic pruritus, and FOP, with regulatory submissions and potential label expansions planned for next year. Market opportunities are expanding through improv
EQUITY | Sep 10, 2026, 03:01 PM UTC
L
MIRM: Multiple late-stage catalysts and commercial expansion set the stage for significant financial growth
A diversified rare disease portfolio is driving strong commercial growth, with multiple near-term clinical and regulatory catalysts expected. LIVMARLI expansion, new launches, and pipeline progress position the business
EQUITY | Sep 09, 2026, 04:22 PM UTC
M
MIRM sees near-term clinical catalysts and LIVMARLI expansion efforts
TradingView News discussion points to a diversified rare-disease portfolio, strong commercial growth, regulatory progress for volixibat and brelovitug, and efforts to expand LIVMARLI’s reach.
EQUITY | Sep 09, 2026, 03:45 PM UTC
L
Mirum Pharmaceuticals appoints Rob Myers as Chief Medical Officer
Mirum Pharmaceuticals (MIRM) appointed Rob Myers, M.D., as Chief Medical Officer, effective September 21, 2026. He will join the leadership team and lead the company’s global medical and clinical development function.
EQUITY | Sep 08, 2026, 12:30 PM UTC
L
MIRUM to participate in upcoming investor conferences
Mirum Pharmaceuticals (Nasdaq: MIRM) announced it will participate in upcoming investor conferences, with selected fireside chats webcast live via its Investors section. An archive will be available.
EQUITY | Sep 02, 2026, 08:01 PM UTC
L
Mirim Pharmaceuticals price target held at $137 by Citizens
Citizens maintained a $137.00-per-share price target for Mirum Pharmaceuticals.
EQUITY | Aug 27, 2026, 02:12 PM UTC
L
MIRM Raises FY26 Guide To $680-700m
MIRM raises FY26 sales guide
EARNINGS | Aug 05, 2026, 08:12 PM UTC
L
Mirum Pharmaceuticals Raises FY2026 Sales Guidance from $660.000M-$680.000M to $680.000M-$700.000M vs $675.249M Est
Mirum Pharmaceuticals (NASDAQ: MIRM ) raises FY2026 sales outlook from $660.000 million-$680.000 million to $680.000 million-$700.000 million vs $675.249 million estimate.
EARNINGS | Aug 05, 2026, 08:04 PM UTC
L
Mirum treatment of primary sclerosing cholangitis granted FDA orphan status
Mirum...
EQUITY | Jul 21, 2026, 06:00 PM UTC
L
Mirum Pharmaceuticals Insider Sold Shares Worth $611,273, According to a Recent SEC Filing
() -- Eric Bjerkholt, CFO, on July 06, 2026, sold 5,000 shares in Mirum Pharmaceuticals (MIRM) for $611,273. Following the Form 4 filing with the SEC, Bjerkholt has control over a total of 42,181 common shares of the com
REGULATION | Jul 08, 2026, 09:13 PM UTC
L
JP Morgan Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $125
JP Morgan analyst Jessica Fye maintains Mirum Pharmaceuticals (NASDAQ: MIRM ) with a Overweight and raises the price target from $115 to $125.
EQUITY | Jul 02, 2026, 02:30 PM UTC